Corcept Therapeutics reported phase 3 results showing relacorilant, an oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in platinum‑resistant ovarian cancer in the Rosella trial. The data meet a second primary endpoint after earlier progression‑free survival gains and bolster the company ahead of an FDA PDUFA date in July 2026. Analysts now model a multibillion‑dollar peak market; relacorilant’s mechanism targets glucocorticoid signaling to enhance chemotherapy effect in resistant tumors.